PETALUMA

Diamond Certified Resource Unveils Comprehensive Summer 2024 Guide for Consumers

Retrieved on: 
Tuesday, May 28, 2024
Diamond, Calendar, Research, ARC, Property management

Petaluma, CA, May 28, 2024 (GLOBE NEWSWIRE) -- American Ratings Corporation (ARC) has launched an expansive online guide to summer-related services on its highly trafficked Diamond Certified Resource website, diamondcertified.org .

Key Points: 
  • Petaluma, CA, May 28, 2024 (GLOBE NEWSWIRE) -- American Ratings Corporation (ARC) has launched an expansive online guide to summer-related services on its highly trafficked Diamond Certified Resource website, diamondcertified.org .
  • Consumers can also get access to exclusive tips from Diamond Certified Expert Contributors and a helpful maintenance calendar, all designed to enhance the summer experience.
  • “That’s why we’ve created this deep category resource guide to help them this summer.
  • And each Diamond Certified company is backed by mediation and the Diamond Certified Performance Guarantee.

Massive Distribution of the 2024 Diamond Certified Directory Begins

Retrieved on: 
Wednesday, April 3, 2024
Diamond, Social media, Research, Insurance, ARC, Directory, Property management

And each Diamond Certified company is backed by mediation and the Diamond Certified Performance Guarantee.

Key Points: 
  • And each Diamond Certified company is backed by mediation and the Diamond Certified Performance Guarantee.
  • As part of their always-free membership, 180,000+ Diamond Certified Preferred Members get immediate access to the 2024 Diamond Certified Directory in their home county as well as two additional counties.
  • Diamond Certified Preferred Membership also includes a member hotline, a double Diamond Certified Performance Guarantee, exclusive digital downloads and more.
  • “The striking, gold-embossed Diamond Certified seal on the cover is a powerful signal of the quality companies that are presented inside.”
    Many Diamond Certified companies see an immediate increase in calling activity when the Diamond Certified Directory is released each year, which translates to more business transactions.

Hydrofarm Holdings Group Announces Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Thursday, February 29, 2024
Hydroponics, CEA, Food, Adjustment, Line of credit, Capital expenditure, GAAP, Public expenditure, Insurance, Bookkeeping

SHOEMAKERSVILLE, Pa., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Hydrofarm Holdings Group, Inc. (“Hydrofarm” or the “Company”) (Nasdaq: HYFM), a leading independent manufacturer and distributor of branded hydroponics equipment and supplies for controlled environment agriculture, today announced financial results for its fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Fourth Quarter 2023 Highlights vs.
  • Gross profit(2) increased to $37.6 million compared to $29.3 million; Gross Profit Margin(2) increased to 16.6% of net sales compared to 8.5%.
  • During 2023, the Company maintained a zero balance on its Revolving Credit Facility and was in compliance with debt covenants as of December 31, 2023.
  • The Company will host a conference call to discuss financial results for the fourth quarter 2023 today at 8:30 a.m. Eastern Time.

RetinalGeniX™ Technologies Inc. Granted a Patent for System And Method For Visualization Of Ocular Anatomy

Retrieved on: 
Thursday, February 22, 2024
Retinitis pigmentosa, Liver, OTCQB, Cancer, Cataract, Alzheimer's disease, MD, Inflammation, Retina, Systemic disease, Patent, Swelling, Huntington's disease, Eye, Geography, Optical flow, Disease, Connective tissue, Biomarker, Anatomy, Kidney disease, Emaciation, Heart, Diagnosis, Conformation, Risk, Atrophy, Element, Cystic fibrosis, Parkinson's disease, Brain, Medical imaging

PETALUMA, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“ RetinalGeniX ” or the “Company”) today announced that it has been granted a patent by the United States Patent and Trademark Office for the Company's System And Method For Visualization Of Ocular Anatomy.

Key Points: 
  • PETALUMA, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“ RetinalGeniX ” or the “Company”) today announced that it has been granted a patent by the United States Patent and Trademark Office for the Company's System And Method For Visualization Of Ocular Anatomy.
  • The present invention relates to systems and methods for visualizing eye anatomy for diagnostic and therapeutic purposes.
  • Furthermore, it allows for the detection and analysis of various conditions of the eye, such as, hydration, innervations, inflammation, circulation, nerve conduction, etc.
  • Some of the best-studied ocular conformational diseases include cataracts in the lens and retinitis pigmentosa in the retina.

Hydrofarm Holdings Group, Inc. to Announce Fourth Quarter and Full Year 2023 Results on February 29, 2024

Retrieved on: 
Thursday, February 15, 2024
Hydroponics

SHOEMAKERSVILLE, Pa., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Hydrofarm Holdings Group, Inc. (“Hydrofarm” or the “Company”) (Nasdaq: HYFM), a leading independent manufacturer and distributor of branded hydroponics equipment and supplies for controlled environment agriculture (“CEA”), today announced that it will host a conference call to review fourth quarter and full year 2023 results on Thursday, February 29, 2024 at 8:30 AM ET.

Key Points: 
  • SHOEMAKERSVILLE, Pa., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Hydrofarm Holdings Group, Inc. (“Hydrofarm” or the “Company”) (Nasdaq: HYFM), a leading independent manufacturer and distributor of branded hydroponics equipment and supplies for controlled environment agriculture (“CEA”), today announced that it will host a conference call to review fourth quarter and full year 2023 results on Thursday, February 29, 2024 at 8:30 AM ET.
  • A press release containing fourth quarter and full year 2023 results will be issued before market open that same day.
  • The conference call can be accessed live over the phone by dialing 1-877-451-6152.
  • The conference call will also be webcast live and archived on the corporate website at www.hydrofarm.com , under the “Investors” section.

Hydrofarm Showcases Sustainable Indoor Gardening Solutions on 'The Balancing Act'

Retrieved on: 
Thursday, February 1, 2024
Gaia, Nature, Gardening, Senior, The Balancing Act, Balancing Act, Television, Atmosphere, Hydroponics, Purpose

As part of the show's sustainable living series, Hydrofarm will spotlight its expertise in indoor, year-round gardening, showcasing high-quality, eco-friendly products.

Key Points: 
  • As part of the show's sustainable living series, Hydrofarm will spotlight its expertise in indoor, year-round gardening, showcasing high-quality, eco-friendly products.
  • Scheduled to air on Lifetime on February 5th, this feature offers a unique opportunity for those passionate about gardening and sustainable living to explore innovative indoor growing techniques.
  • "We're excited to join 'The Balancing Act' to showcase our commitment to indoor gardening and sustainable living," said Danielle Caldwell, Senior E-Commerce & Garden Center Account Manager at Hydrofarm.
  • This segment is set to offer valuable insights into Hydrofarm's products and the broader potential of indoor gardening for a sustainable lifestyle.

Hydrofarm Holdings Group to Participate in the 2024 ICR Conference

Retrieved on: 
Tuesday, January 2, 2024
Hydroponics, Conference

SHOEMAKERSVILLE, Pa., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Hydrofarm Holdings Group, Inc. (“Hydrofarm” or the “Company”) (Nasdaq: HYFM), a leading independent manufacturer and distributor of branded hydroponics equipment and supplies for controlled environment agriculture, today announced that the Company will participate in a fireside chat discussion at the 2024 ICR Conference in Orlando, Florida.

Key Points: 
  • SHOEMAKERSVILLE, Pa., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Hydrofarm Holdings Group, Inc. (“Hydrofarm” or the “Company”) (Nasdaq: HYFM), a leading independent manufacturer and distributor of branded hydroponics equipment and supplies for controlled environment agriculture, today announced that the Company will participate in a fireside chat discussion at the 2024 ICR Conference in Orlando, Florida.
  • Hydrofarm’s discussion will begin at 2:00 PM ET on Monday, January 8, 2024.
  • This fireside chat will be webcast live and available for replay on the corporate website at www.hydrofarm.com , under the “Investors” section, or directly through the ICR Conference website at www.icrconference.com .

RetinalGeniX™ Technologies Inc. Contracts With MEDsan, Inc. to Provide Diagnostic Testing Services for Its Institutional Review Board to Conduct a Study to Personalize Medical Evaluations for Patients Receiving Treatment for Wet Macular Degeneration

Retrieved on: 
Tuesday, December 26, 2023
Vance DeGeneres, Pupil, Physician, AMD, Trial of the century, MD, IRB, OTCQB, Doctor of Philosophy, Institutional review board, Patient, Paratriathlon, Diabetes, Pharmaceutical industry

“We are pleased to extend our services into testing for wet macular degeneration, a field that we have been looking at for quite some time.

Key Points: 
  • “We are pleased to extend our services into testing for wet macular degeneration, a field that we have been looking at for quite some time.
  • RetinalGeniX has also filed two provisional patents related to these studies and formed an institutional review board to launch a 390-patient clinical study intended to validate the relative suitability of anti-VEGF ocular injection treatments for patient candidates with wet AMD.
  • Jerry Katzman, MD, Chairman, President and CEO of RetinalGeniX said “MEDsan is a next-generation diagnostic CLIA-approved laboratory services facility equipped with the most technically advanced diagnostic equipment in the pharmaco-genetic space.
  • Dr. Jonathan Brenner, Ph.D., and his team are specialists running diagnostic panels and dovetails RetinalGeniX’s clinical agenda to clinical study requirements.

RetinalGeniX Technologies Inc. Appoints Anatoly Dritschilo, M.D. to the Company’s Medical Advisory Board

Retrieved on: 
Thursday, December 21, 2023
Consultant, Pupil, Drug development, Physician, Georgetown University, Research, Breast, Medical director, Radiation therapy, AMD, MedStar Georgetown University Hospital, Trial of the century, Chemical engineering, College, Eye, Radiation, National academy, Medicine, University, Prostate, OTCQB, Cancer, Interim, Teaching hospital, Patient, Central nervous system, Diagnosis, NCI, Paratriathlon, Diabetes

PETALUMA, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX Technologies Inc. (OTCQB: RTGN) (“RetinalGeniX” or the “Company”), today announced that Anatoly Dritschilo, M.D.

Key Points: 
  • PETALUMA, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX Technologies Inc. (OTCQB: RTGN) (“RetinalGeniX” or the “Company”), today announced that Anatoly Dritschilo, M.D.
  • has joined the Company’s Medical Advisory Board.
  • RetinalGeniX is an ophthalmic research and development med-device and therapeutic drug development company focused on developing High-Resolution Retinal Imaging and Pharmaco-Genetic Mapping™ technologies.
  • Dr. Dritschilo is the CEO and Chairman of the Board of Directors of Shuttle Pharmaceuticals Holdings, Inc.

RetinalGeniX Technologies Inc. Appoints Dessy Boneva, MD, FACS to the Board of Directors

Retrieved on: 
Monday, December 4, 2023
Ophthalmology, Systemic disease, Trauma, USF, Pupil, Drug development, Physician, Software, School, The Wall Street Journal, Injury, Student, Graduate medical education, AMD, Surgeon, Trial of the century, University, GME, Mathematics, Dean, The International, OTCQB, Ivy League, American College, Publication, Patient, Diagnosis, Nursing care plan, Medicine, Paratriathlon, Diabetes

PETALUMA, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX Technologies Inc. (OTCQB: RTGN) (“RetinalGeniX” or the “Company”), today announced that Dessislava (Dessy) Boneva, M.D.

Key Points: 
  • PETALUMA, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX Technologies Inc. (OTCQB: RTGN) (“RetinalGeniX” or the “Company”), today announced that Dessislava (Dessy) Boneva, M.D.
  • RetinalGeniX is an ophthalmic research and development med-device and therapeutic drug development company focused on developing High-Resolution Retinal Imaging and Pharmaco-Genetic Mapping™ technologies.
  • Dr. Boneva said, “I am very excited about joining the RetinalGeniX Board of Directors.
  • Jerry Katzman MD, Chairman, President, and CEO of RetinalGeniX Technologies Inc., said, “We are delighted to welcome Dessy aboard.